Polyethylene Glycol
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
Polyethylene glycol: From Constipation and Dry Eye to Congenital Ichthyosiform Erythroderma
One-Sentence Summary
Polyethylene glycol is an osmotic agent used as a laxative for constipation and as a lubricant in dry eye products. The TxGNN model predicts it may be effective for congenital ichthyosiform erythroderma, but no clinical trials and no publications currently support this direction, so the prediction rests on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Constipation disorder, dry eye syndrome, xerophthalmia (the India license records contain no approved indication text) |
| Predicted New Indication | Congenital ichthyosiform erythroderma |
| TxGNN Prediction Score | 0.9903 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, polyethylene glycol is an osmotic agent and a hydrating or lubricating ingredient. Its efficacy in constipation (as an osmotic laxative) and in dry eye (as a lubricant) is established, and it may mechanistically be applicable to dry, scaly skin conditions.
The only rationale available is speculative. Because polyethylene glycol attracts and holds water, it could help hydrate a dry, scaly stratum corneum, as seen in congenital ichthyosiform erythroderma. This is a hypothesis, not a demonstrated link.
Ichthyosis is a genetic keratinization disorder (for example, TGM1 and ALOX12B/ALOXE3 variants) with a defective skin barrier. Moisturizing the skin eases symptoms but does not modify the disease. The high TxGNN score is a model-based prediction, and the data compiled for this report contain no clinical or literature support for it. The prediction’s similarity to the original indications and its route compatibility have not been assessed. All registered products are oral, other (powder/liquid), or ophthalmic, and none is a dermatological product.
India Market Information
All 20 registrations are valid single-ingredient products. The license records contain no approved indication text. Five main authorizations are listed below.
| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---|---|---|---|
| 121044 | Looz Peg Oral Solution Orange | Oral solution, 200 ml bottle | Intas Pharmaceuticals Ltd |
| 121797 | Laxolite 10gm Oral Laxative Liquid Sugar Free | Liquid, 100 ml bottle | J B Chemicals and Pharmaceuticals Ltd |
| 113911 | Junior Cipeg Powder for Oral Solution | Powder for oral solution, 121.1 gm bottle | Cipla Ltd |
| 175323 | Pegsure Sachet Orange | Powder, 17 gm sachet | Veterix Lifesciences Private Limited |
| 39940 | C-Well Eye Drop | Eye drop, 10 ml bottle | Wellona Pharmaceutical Private Limited |
The other 15 registrations include one further laxative powder (Scilax) and 14 additional eye drops, all in 10 ml presentations.
Safety Considerations
Contraindications (from drug-disease associations in the knowledge graph, not from label text): The following conditions are linked to polyethylene glycol as contraindications in the knowledge graph:
- Gastrointestinal: ileus, paralytic ileus, intestinal obstruction, toxic megacolon, pyloric stenosis, familial visceral myopathy, appendicitis
- Cardiovascular: hypertension, hypertensive disorder, congestive heart failure, cardiovascular disease, heart disease
- Renal and metabolic: kidney disease, anuria, pyoureter, nephrocalcinosis, hypercalcemia, phosphorus metabolism disease, potassium deficiency disease, hyperglycemia, diabetes mellitus, diabetic ketoacidosis
- Endocrine: hyperthyroidism, Graves disease, thyrotoxicosis
- Neurological: epilepsy
- Ocular: angle-closure (closed-angle) glaucoma, eye infectious disease, conjunctivitis
These associations come from a model knowledge graph and may reflect other products or components. They should be verified against the official package insert.
No drug interaction records were found. Please refer to the package insert for warnings and other safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by the model score. There are no clinical trials or publications, the mechanistic link is speculative, and the benefit would at most be symptomatic moisturization of a genetic barrier disorder. No registered product has a dermatological route.
To proceed, the following is needed:
- Package insert warnings and contraindications from the India regulator (currently a blocking gap for safety screening)
- Mechanism of action data from DrugBank
- A literature and trial search for polyethylene glycol or PEG-based topical products in ichthyosis
- An assessment of route compatibility (a topical formulation would be needed) and similarity to the original indications
- Preclinical or small exploratory data showing a benefit beyond ordinary emollients
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.